Cabaletta Bio provided updates for CABA-201, saying that two out of four pemphigus vulgaris patients treated with CABA-201 without preconditioning chemo achieved virtually complete and durable remissions, Cantor Fitzgerald tells investors in a research note. The firm, which has an Overweight rating and $30 price target on the shares, says concerns regarding a financing overhang should be meaningfully addressed with the $150M offering in addition to the $135M on its balance sheet and $120M from warrant exercises.
